WO2025096975 - COMPOSITIONS AND METHODS OF ENHANCING IMMUNE CELL THERAPIES BY RUNX2 MODULATION
National phase entry is expected:
Publication Number
WO/2025/096975
Publication Date
08.05.2025
International Application No.
PCT/US2024/054159
International Filing Date
01.11.2024
Title **
[English]
COMPOSITIONS AND METHODS OF ENHANCING IMMUNE CELL THERAPIES BY RUNX2 MODULATION
[French]
COMPOSITIONS ET PROCÉDÉS D'AMÉLIORATION DE THÉRAPIES CELLULAIRES IMMUNITAIRES PAR MODULATION RUNX2
Applicants **
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
NATIONAL JEWISH HEALTH
Inventors
FRY, Terry J.
DEGOLIER, Kole R.
SCOTT-BROWNE, James P.
Priority Data
63/595,612
02.11.2023
US
63/640,437
30.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3296 | |
| EPO | Filing, Examination, Granting | 18053 | |
| Japan | Filing, Examination, Granting | 2555 | |
| South Korea | Filing, Examination, Granting | 2914 | |
| USA | Filing, Examination, Granting | 9790 |
Total:
36,608
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates generally to compositions and methods of enhancing potency of immune cell therapies by Runx2 modulation.[French]
La présente divulgation concerne, de manière générale, des compositions et des procédés d'amélioration de la puissance de thérapies cellulaires immunitaires par modulation Runx2.